SPYPBO-101
Sponsors
Spyre Therapeutics Inc.
Conditions
Moderately to Severely Active Ulcerative ColitisUlcerative colitis (Inflammatory Bowel Disease)
Phase 2
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
RecruitingCTIS2025-521242-26-00
Start: 2025-11-27Target: 238Updated: 2025-11-27
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
Not yet recruitingCTIS2025-524640-35-00
Target: 102Updated: 2026-06-17